181 related articles for article (PubMed ID: 32047957)
41. Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients.
Ma C; Yu R; Li J; Guo J; Xu J; Wang X; Liu P
J Surg Oncol; 2022 Mar; 125(4):754-765. PubMed ID: 34811745
[TBL] [Abstract][Full Text] [Related]
42. Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsuchiya H; Tsumura H
Clin Orthop Relat Res; 2012 Aug; 470(8):2288-94. PubMed ID: 22415727
[TBL] [Abstract][Full Text] [Related]
43. Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients.
Wu PK; Chen WM; Chen CF; Lee OK; Haung CK; Chen TH
Jpn J Clin Oncol; 2009 Aug; 39(8):514-22. PubMed ID: 19525290
[TBL] [Abstract][Full Text] [Related]
44. Lack of Toll-like receptor 4 decreases lipopolysaccharide-induced bone resorption in C3H/HeJ mice in vivo.
Nakamura H; Fukusaki Y; Yoshimura A; Shiraishi C; Kishimoto M; Kaneko T; Hara Y
Oral Microbiol Immunol; 2008 Jun; 23(3):190-5. PubMed ID: 18402604
[TBL] [Abstract][Full Text] [Related]
45. Presentation and Long-term Outcome of High-grade Osteosarcoma: A Single-institution Experience.
Berlanga P; Cañete A; Díaz R; Salom M; Baixauli F; Gómez J; Llavador M; Castel V
J Pediatr Hematol Oncol; 2015 Jul; 37(5):e272-7. PubMed ID: 25374283
[TBL] [Abstract][Full Text] [Related]
46. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
[TBL] [Abstract][Full Text] [Related]
47. Inhibition by interleukin-18 of the growth of Dunn osteosarcoma cells.
Okamoto T; Yamada N; Tsujimura T; Sugihara A; Nishizawa Y; Ueda H; Kashiwamura S; Tsutsui H; Futani H; Maruo S; Okamura H; Terada N
J Interferon Cytokine Res; 2004 Mar; 24(3):161-7. PubMed ID: 15035849
[TBL] [Abstract][Full Text] [Related]
48. TLR4 is involved in the pathogenic effects observed in a murine model of antiphospholipid syndrome.
Xie H; Kong X; Zhou H; Xie Y; Sheng L; Wang T; Xia L; Yan J
Clin Immunol; 2015 Oct; 160(2):198-210. PubMed ID: 26065621
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
50. ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity.
Zucchini C; Manara MC; Cristalli C; Carrabotta M; Greco S; Pinca RS; Ferrari C; Landuzzi L; Pasello M; Lollini PL; Gambarotti M; Donati DM; Scotlandi K
J Exp Clin Cancer Res; 2019 Dec; 38(1):503. PubMed ID: 31878963
[TBL] [Abstract][Full Text] [Related]
51. [Pulmonary metastases in osteosarcoma patients--treatment results].
Szafrański A; Woźniak W; Rychłowska-Pruszyńska M
Przegl Lek; 2004; 61 Suppl 2():24-8. PubMed ID: 15686042
[TBL] [Abstract][Full Text] [Related]
52. Vitronectin significantly influences prognosis in osteosarcoma.
Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
[TBL] [Abstract][Full Text] [Related]
53. Role of Toll-like receptor 4 in induction of cell-mediated immunity and resistance to Brucella abortus infection in mice.
Campos MA; Rosinha GM; Almeida IC; Salgueiro XS; Jarvis BW; Splitter GA; Qureshi N; Bruna-Romero O; Gazzinelli RT; Oliveira SC
Infect Immun; 2004 Jan; 72(1):176-86. PubMed ID: 14688095
[TBL] [Abstract][Full Text] [Related]
54. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
Mata-Haro V; Cekic C; Martin M; Chilton PM; Casella CR; Mitchell TC
Science; 2007 Jun; 316(5831):1628-32. PubMed ID: 17569868
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
Machado I; López-Guerrero JA; Scotlandi K; Picci P; Llombart-Bosch A
Virchows Arch; 2018 May; 472(5):815-824. PubMed ID: 29445891
[TBL] [Abstract][Full Text] [Related]
56. Ginsenosides Rg1 and Re act as adjuvant via TLR4 signaling pathway.
Su F; Yuan L; Zhang L; Hu S
Vaccine; 2012 Jun; 30(27):4106-12. PubMed ID: 22472794
[TBL] [Abstract][Full Text] [Related]
57. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
58. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
59. Identification of two immune subtypes in osteosarcoma based on immune gene sets.
Yang M; Cao Y; Wang Z; Zhang T; Hua Y; Cai Z
Int Immunopharmacol; 2021 Jul; 96():107799. PubMed ID: 34162161
[TBL] [Abstract][Full Text] [Related]
60. LPS alters the immuno-phenotype of glioma and glioma stem-like cells and induces in vivo antitumor immunity via TLR4.
Han S; Wang C; Qin X; Xia J; Wu A
J Exp Clin Cancer Res; 2017 Jun; 36(1):83. PubMed ID: 28641579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
